Myelofibrosis Clinical Trials

43 recruiting

Myelofibrosis Trials at a Glance

73 actively recruiting trials for myelofibrosis are listed on ClinicalTrialsFinder across 6 cities in 39 countries. The largest study group is Phase 2 with 30 trials, with the heaviest enrollment activity in New York, Houston, and Bologna. Lead sponsors running myelofibrosis studies include M.D. Anderson Cancer Center, Masonic Cancer Center, University of Minnesota, and Memorial Sloan Kettering Cancer Center.

Browse myelofibrosis trials by phase

Treatments under study

About Myelofibrosis Clinical Trials

Looking for clinical trials for Myelofibrosis? There are currently 43 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Myelofibrosis trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Myelofibrosis clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 73 trials

Recruiting
Phase 1Phase 2

A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis

Myelofibrosis
Sumitomo Pharma America, Inc.240 enrolled84 locationsNCT04176198
Recruiting
Phase 1Phase 2

Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia

Myelodysplastic SyndromesMyelofibrosisAnemia+4 more
Disc Medicine, Inc150 enrolled24 locationsNCT05320198
Recruiting
Phase 1

A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms

Myelofibrosis (MF)Polycythemia Vera (PV)Myeloproliferative Neoplasms (MPNs)
Prelude Therapeutics100 enrolled1 locationNCT07469891
Recruiting
Phase 2

A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)

Myelodysplastic/Myeloproliferative NeoplasmPolycythemia VeraPrimary Myelofibrosis+5 more
National Cancer Institute (NCI)62 enrolled30 locationsNCT06661915
Recruiting
Phase 1Phase 2

A Study of Roginolisib in Combination With Ruxolitinib in Patients With Myelofibrosis (MF) Who Are Unresponsive to JAK Inhibitors

Myelofibrosis (MF)
iOnctura26 enrolled11 locationsNCT06887803
Recruiting
Not Applicable

Feasibility Trial of Extracorporeal Iron Purification in Patients With Myelodysplastic Syndrome or Myelofibrosis

Myelodysplastic SyndromeMyelofibrosis
Hospices Civils de Lyon13 enrolled2 locationsNCT06781099
Recruiting
Phase 2

Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Myelofibrosis

Primary MyelofibrosisMyelofibrosis; Primary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis
GlaxoSmithKline68 enrolled33 locationsNCT06517875
Recruiting
Phase 1

UAB 2419-CD34 Selection Using the Automated CliniMACS Prodigy

AMLMyelodysplastic SyndromesCML+3 more
University of Alabama at Birmingham50 enrolled1 locationNCT06047886
Recruiting
Phase 1

To Evaluate the Pharmacokinetics and Safety of TQ05105 Tablet in Hepatic Impairment Subjects

Myelofibrosis
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.24 enrolled2 locationsNCT07480824
Recruiting
Phase 1Phase 2

A Study of Ruxolitinib in Combination With Ulixertinib in People With Myelofibrosis

Myelofibrosis
Memorial Sloan Kettering Cancer Center37 enrolled9 locationsNCT06773195
Recruiting
Phase 3

A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017)

MyelofibrosisPolycythemia VeraPrimary Myelofibrosis+3 more
Merck Sharp & Dohme LLC400 enrolled21 locationsNCT06351631
Recruiting
Phase 1

Momelotinib During and After HCT in Myelofibrosis

MyelofibrosisHematopoietic Cell Transplantation (HCT)
Massachusetts General Hospital28 enrolled1 locationNCT07104799
Recruiting
Not Applicable

A Telehealth Advance Care Planning Intervention

Acute Myeloid LeukemiaMyelodysplastic SyndromesMyelofibrosis+2 more
University of Rochester207 enrolled1 locationNCT05875805
Recruiting

Registry Platform Myelofibrosis and Anemia

MyelofibrosisAnemiaPrimary Myelofibrosis+4 more
iOMEDICO AG200 enrolled1 locationNCT06976918
Recruiting
Phase 2

Curcumin to Improve Inflammation and Symptoms in Patients With Clonal Cytopenia of Undetermined Significance, Low Risk Myelodysplastic Syndrome, and Myeloproliferative Neoplasms

Myelodysplastic SyndromeMyelofibrosisPolycythemia Vera+2 more
University of Southern California30 enrolled2 locationsNCT06063486
Recruiting
Phase 1

A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant

Hematopoietic and Lymphatic System NeoplasmAcute Lymphoblastic LeukemiaAcute Myeloid Leukemia+9 more
City of Hope Medical Center46 enrolled3 locationsNCT07020533
Recruiting
Phase 1

A Phase 1 Study of AJ1-11095 in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)

Primary Myelofibrosis
Ajax Therapeutics, Inc.76 enrolled16 locationsNCT06343805
Recruiting
Phase 3

AVAJAK: Apixaban/Rivaroxaban Versus Aspirin for Primary Prevention of Thrombo-embolic Complications in JAK2V617F-positive Myeloproliferative Neoplasms

Polycythemia VeraEssential ThrombocythemiaPrefibrotic/Early Primary Myelofibrosis+1 more
University Hospital, Brest1,308 enrolled42 locationsNCT05198960
Recruiting
Phase 2

Study of Canakinumab in Patients With Myelofibrosis

Primary MyelofibrosisPost-essential Thrombocythemia MyelofibrosisET-MF+2 more
John Mascarenhas14 enrolled8 locationsNCT05467800
Recruiting
Phase 2

A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation

LymphomaMyelofibrosisAML (Acute Myelogenous Leukemia)+8 more
Center for International Blood and Marrow Transplant Research358 enrolled13 locationsNCT06859424